1. [KDR silencing supresses the tumor growth of prostate cancer cell line PC-3 in nude mice].
- Author
-
Xie G, Yi W, Liu X, Guo Z, and Miao Y
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, RNA Interference, Vascular Endothelial Growth Factor Receptor-2 genetics, Vascular Endothelial Growth Factor Receptor-2 metabolism, Gene Silencing, Prostatic Neoplasms pathology, Vascular Endothelial Growth Factor Receptor-2 deficiency
- Abstract
Objective: To study the change in the tumor growth of prostate cancer cell line PC-3 in nude mice xenografts after kinase domain receptor (KDR) silencing by RNA interference., Methods: A total of 15 5-week-old male nude mice were randomly divided into normal PC-3 cell group (negative control), RNA interference group and pSilencer3.1-NC group, with 5 mice in every group. The nude mice were respectively treated with subcutaneous injection of 0.5 mL (2.0×10(7);/mL) normal PC-3 cells, and the same volume of PC-3 cells transfected with pSilencer3.1-KDR and pSilencer3.1-NC vectors, respectively. By measuring the tumor volumes every 3 d and the tumor weights after 4 weeks, we recorded tumor formation rate, tumor growth rate and mean tumor weight. The expression of KDR at both mRNA and protein levels was detected by RT-PCR and Western blotting, respectively., Results: Tumor growth was significantly slower in the pSilencer3.1-KDR group than in the negative control group and the pSilencer3.1-NC group. After 4 weeks, the mean volume of tumor in the pSilencer3.1-KDR group was significantly smaller than that in the other two groups (0.28 cm(3); vs 0.715 cm(3); and 0.721 cm(3);, P<0.01), so was the mean weight of tumor (0.14 g vs 0.635 g and 0.648 g, P<0.01). In addition, KDR mRNA and protein expressions significantly decreased., Conclusion: The tumor growth in nude mice xenografts can be efficiently inhibited by KDR silencing mediated by RNAi, so the suppression of KDR expression might be a promising strategy for the treatment of human prostate cancer.
- Published
- 2013